Gliza MF Tablet is a combination oral antidiabetic medication containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea derivative, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic action of these two agents provides effective control of blood glucose levels in patients inadequately managed by diet and exercise alone. Gliza MF is particularly beneficial for patients who require dual mechanisms of action to achieve optimal glycemic targets. It should be administered with meals to minimize gastrointestinal side effects commonly associated with Metformin. Regular monitoring of blood glucose levels, renal function, and hepatic parameters is recommended during therapy to ensure efficacy and safety. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Gliza MF is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to its components. Proper adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes and reduces the risk of diabetes-related complications.